{ "dataset": { "name": "GLP-1 & Obesity Drug Pipeline", "url": "https://nphla.com/trackers/glp1-obesity-pipeline", "description": "Phase 2 and phase 3 clinical trials of GLP-1, amylin and other incretin-based obesity and metabolic medicines registered on ClinicalTrials.gov, with each study’s phase, recruitment status, sponsor and latest registry update.", "publisher": "National Pharmacy Health & Leadership Alliance", "howToCite": "National Pharmacy Health & Leadership Alliance (NPHLA). nphla.com. “GLP-1 & Obesity Drug Pipeline.” Updated Oct 1, 2026. https://nphla.com/trackers/glp1-obesity-pipeline. Accessed October 1, 2026.", "kind": "GLP-1 & obesity drug pipeline (ClinicalTrials.gov)", "dataOrigin": "NPHLA analysis of public data", "jurisdiction": "International / multiple", "methodology": "The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) on the schedule set in the Source Registry: one broad search for obesity and incretin therapies (GLP-1, semaglutide, tirzepatide, retatrutide, orforglipron, amylin, cagrilintide, survodutide) and a separate search for each metabolic topic that has a trial query, such as retatrutide or orforglipron. Each study is stored with its registry fields exactly as published: title, phase, overall status, sponsor, conditions, interventions and the date of its last registry update.\n\nWhen a study’s overall status changes, or results are first posted, the change is recorded with the date the pipeline detected it. This tracker lists studies on the Metabolic desk whose registered phase includes phase 2 or phase 3 (combined phase 2/3 studies included). Nothing in the table is edited by hand.", "coverage": "Studies listed on ClinicalTrials.gov — from the United States and other countries — that match the search terms above, from the date tracking of each search began. Phase 2 and phase 3 only. Phase 1 and phase 4 studies, studies described with other terms and studies registered only in other registries are not included.", "limitations": "Registry records are maintained by trial sponsors and can lag events; the status shown is the sponsor’s registry status at the last check, not an assessment of the trial. Searches can include studies of these medicines for conditions other than obesity and can miss studies that use different terms. Every therapy in a trial is investigational for the use being studied. Not medical advice.", "updateFrequency": "Registry searches run every 6 to 12 hours, as configured in the Source Registry; the table reflects each completed check.", "selection": "ClinicalTrials.gov studies followed by Trial Watch in phase 2 and phase 3 on the metabolic desk.", "systemCheckedAt": "2026-10-01T15:35:08.009Z", "editoriallyReviewedAt": null, "editorialReview": "pending", "generatedAt": "2026-10-01T19:35:29.854Z", "recordCount": 82, "notAdvice": "Professional information compiled from public sources. Not medical, legal or regulatory advice; always confirm in the primary source." }, "columns": [ { "key": "phase", "label": "Phase" }, { "key": "sponsor", "label": "Sponsor" } ], "records": [ { "key": "trial:NCT07734792", "record": "TOPAZ: Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial", "subtitle": "NCT07734792", "detail": "Conditions: Acute Ischemic Stroke (AIS). Interventions: Tirzepatide; Standard Medical Care (SMC)", "status": "Not yet recruiting", "fields": { "phase": "Phase 2 / Phase 3", "sponsor": "yifang zhu", "enrollment": "726", "nctId": "NCT07734792" }, "jurisdiction": null, "date": "2026-10-01T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07734792", "url": "https://clinicaltrials.gov/study/NCT07734792", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.468Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06632444", "record": "LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis", "subtitle": "NCT06632444", "detail": "Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH); Liver Fibrosis. Interventions: Survodutide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Boehringer Ingelheim", "enrollment": "1800", "nctId": "NCT06632444" }, "jurisdiction": null, "date": "2026-10-01T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06632444", "url": "https://clinicaltrials.gov/study/NCT06632444", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.458Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07112872", "record": "A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes", "subtitle": "NCT07112872", "detail": "Conditions: Type 2 Diabetes Mellitus. Interventions: RO7795081; Semaglutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Hoffmann-La Roche", "enrollment": "330", "nctId": "NCT07112872" }, "jurisdiction": null, "date": "2026-10-01T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07112872", "url": "https://clinicaltrials.gov/study/NCT07112872", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.436Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07820358", "record": "SWIFT: Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer", "subtitle": "NCT07820358", "detail": "Conditions: Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endo…. Interventions: Semaglutide (Wegovy) weekly injection; LNG-IUD (Progestin); Structured Weight Loss Program", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "The Methodist Hospital Research Institute", "enrollment": "48", "nctId": "NCT07820358" }, "jurisdiction": null, "date": "2026-10-01T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07820358", "url": "https://clinicaltrials.gov/study/NCT07820358", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.366Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06109311", "record": "ACHIEVE-5: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor", "subtitle": "NCT06109311", "detail": "Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "546", "nctId": "NCT06109311" }, "jurisdiction": null, "date": "2026-10-01T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06109311", "url": "https://clinicaltrials.gov/study/NCT06109311", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.356Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05254314", "record": "GATA-3: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)", "subtitle": "NCT05254314", "detail": "Conditions: Asthma. Interventions: Semaglutide Pen Injector 2.4mg weekly; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Vanderbilt University Medical Center", "enrollment": "100", "nctId": "NCT05254314" }, "jurisdiction": null, "date": "2026-10-01T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05254314", "url": "https://clinicaltrials.gov/study/NCT05254314", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.345Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07775404", "record": "Elecoglipron: A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus", "subtitle": "NCT07775404", "detail": "Conditions: Obesity; Overweight. Interventions: Elecoglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "AstraZeneca", "enrollment": "351", "nctId": "NCT07775404" }, "jurisdiction": null, "date": "2026-10-01T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07775404", "url": "https://clinicaltrials.gov/study/NCT07775404", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.325Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07752979", "record": "Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities", "subtitle": "NCT07752979", "detail": "Conditions: Obesity; Overweight. Interventions: ABBV-295; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "AbbVie", "enrollment": "360", "nctId": "NCT07752979" }, "jurisdiction": null, "date": "2026-10-01T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07752979", "url": "https://clinicaltrials.gov/study/NCT07752979", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.388Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06323174", "record": "REIMAGINE 1: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise", "subtitle": "NCT06323174", "detail": "Conditions: Type 2 Diabetes. Interventions: Cagrilintide; Semaglutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "189", "nctId": "NCT06323174" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06323174", "url": "https://clinicaltrials.gov/study/NCT06323174", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:20.487Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.780Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07817251", "record": "Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema", "subtitle": "NCT07817251", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "210", "nctId": "NCT07817251" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07817251", "url": "https://clinicaltrials.gov/study/NCT07817251", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:20.487Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.750Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07011667", "record": "A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term", "subtitle": "NCT07011667", "detail": "Conditions: Obesity. Interventions: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "609", "nctId": "NCT07011667" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07011667", "url": "https://clinicaltrials.gov/study/NCT07011667", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.753Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07850050", "record": "SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight", "subtitle": "NCT07850050", "detail": "Conditions: Obesity. Interventions: Survodutide; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Boehringer Ingelheim", "enrollment": "600", "nctId": "NCT07850050" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07850050", "url": "https://clinicaltrials.gov/study/NCT07850050", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.792Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07564414", "record": "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight", "subtitle": "NCT07564414", "detail": "Conditions: Obesity; Type 2 Diabetes. Interventions: Cagrisema; Semaglutide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "2500", "nctId": "NCT07564414" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07564414", "url": "https://clinicaltrials.gov/study/NCT07564414", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:20.487Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.690Z", "change": null, "origin": "automated" }, { "key": "trial:NCT03449251", "record": "DEFINE: A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin", "subtitle": "NCT03449251", "detail": "Conditions: Cardiovascular Diseases; Type 2 Diabetes Mellitus. Interventions: Apelin; Relaxin; Normal saline; Verapamil; LN Monomethyl arginine", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Cambridge University Hospitals NHS Foundation Trust", "enrollment": "170", "nctId": "NCT03449251" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT03449251", "url": "https://clinicaltrials.gov/study/NCT03449251", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.680Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07850063", "record": "ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease", "subtitle": "NCT07850063", "detail": "Conditions: Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease. Interventions: Survodutide; Placebo matching survodutide", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Boehringer Ingelheim", "enrollment": "600", "nctId": "NCT07850063" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07850063", "url": "https://clinicaltrials.gov/study/NCT07850063", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.920Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07253285", "record": "A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight", "subtitle": "NCT07253285", "detail": "Conditions: Overweight; Obesity. Interventions: Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "460", "nctId": "NCT07253285" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07253285", "url": "https://clinicaltrials.gov/study/NCT07253285", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.850Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06077864", "record": "A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)", "subtitle": "NCT06077864", "detail": "Conditions: Obesity. Interventions: survodutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Boehringer Ingelheim", "enrollment": "5531", "nctId": "NCT06077864" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06077864", "url": "https://clinicaltrials.gov/study/NCT06077864", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.538Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05567796", "record": "REDEFINE 1: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight", "subtitle": "NCT05567796", "detail": "Conditions: Obesity. Interventions: Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "3400", "nctId": "NCT05567796" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05567796", "url": "https://clinicaltrials.gov/study/NCT05567796", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T15:35:07.322Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T15:35:07.641Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06771115", "record": "Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity", "subtitle": "NCT06771115", "detail": "Conditions: Obesity. Interventions: Placebo; VTX3232 30 mg; Placebo in combination with semaglutide; VTX3232 30 mg in combination with semaglutide", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Zomagen Biosciences Ltd.", "enrollment": "175", "nctId": "NCT06771115" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06771115", "url": "https://clinicaltrials.gov/study/NCT06771115", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:20.487Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:21.027Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07527910", "record": "A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD", "subtitle": "NCT07527910", "detail": "Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Interventions: ALN-PNP; Tirzepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Regeneron Pharmaceuticals", "enrollment": "204", "nctId": "NCT07527910" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07527910", "url": "https://clinicaltrials.gov/study/NCT07527910", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.846Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.881Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05305794", "record": "TOLEDDO: Effect of Weekly GLP1 Agonist Treatment in \"Double Diabetes\"", "subtitle": "NCT05305794", "detail": "Conditions: Double Diabetes. Interventions: Insulin + semaglutide treatment; Usual insulin treatment; Biological check-up", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Centre Hospitalier Universitaire Dijon", "enrollment": "76", "nctId": "NCT05305794" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05305794", "url": "https://clinicaltrials.gov/study/NCT05305794", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.824Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.826Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07845500", "record": "A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity", "subtitle": "NCT07845500", "detail": "Conditions: Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity. Interventions: Semaglutide; Tirzepatide; Berobenatide", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Pfizer", "enrollment": "660", "nctId": "NCT07845500" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07845500", "url": "https://clinicaltrials.gov/study/NCT07845500", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:20.487Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:21.086Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06603571", "record": "A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes", "subtitle": "NCT06603571", "detail": "Conditions: Obesity; Overweight. Interventions: LY3841136; Tirzepatide; Placebo", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Eli Lilly and Company", "enrollment": "367", "nctId": "NCT06603571" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06603571", "url": "https://clinicaltrials.gov/study/NCT06603571", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.846Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.009Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07846865", "record": "TIRZE-PAP: Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial", "subtitle": "NCT07846865", "detail": "Conditions: Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive. Interventions: Continuous Positive Airway Pressure; Tirzepatide", "status": "Not yet recruiting", "fields": { "phase": "Phase 2 / Phase 3", "sponsor": "Woolcock Institute of Medical Research", "enrollment": "256", "nctId": "NCT07846865" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07846865", "url": "https://clinicaltrials.gov/study/NCT07846865", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.846Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.943Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07171723", "record": "SILENCED: Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment", "subtitle": "NCT07171723", "detail": "Conditions: Obesity &Amp; Overweight. Interventions: Liver-Expressed Antimicrobial Peptide 2 (LEAP2); Placebo (saline)", "status": "Completed", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "University Hospital, Gentofte, Copenhagen", "enrollment": "24", "nctId": "NCT07171723" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07171723", "url": "https://clinicaltrials.gov/study/NCT07171723", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:20.487Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:21.004Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07724340", "record": "A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity", "subtitle": "NCT07724340", "detail": "Conditions: Adults With Overweight/Obesity and Type 2 Diabetes. Interventions: AT673 low dose; AT673 high dose; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Antag Therapeutics", "enrollment": "150", "nctId": "NCT07724340" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07724340", "url": "https://clinicaltrials.gov/study/NCT07724340", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:20.487Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.975Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07685808", "record": "Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes", "subtitle": "NCT07685808", "detail": "Conditions: Overweight or Obesity. Interventions: Olatorepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Regeneron Pharmaceuticals", "enrollment": "360", "nctId": "NCT07685808" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07685808", "url": "https://clinicaltrials.gov/study/NCT07685808", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:17.129Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:17.281Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07845994", "record": "SEMAFORCRANIO: SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years", "subtitle": "NCT07845994", "detail": "Conditions: Craniopharyngioma, Child. Interventions: Semaglutide (Wegovy) weekly injection; Placebo weekly Injection", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "University Hospital, Angers", "enrollment": "50", "nctId": "NCT07845994" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07845994", "url": "https://clinicaltrials.gov/study/NCT07845994", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:20.487Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.870Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06745128", "record": "Tirzepatide for Obesity and Meth Use Disorder", "subtitle": "NCT06745128", "detail": "Conditions: Obesity; Methamphetamine Use Disorder. Interventions: Tirzepatide", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "University of Texas Southwestern Medical Center", "enrollment": "35", "nctId": "NCT06745128" }, "jurisdiction": null, "date": "2026-09-28T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06745128", "url": "https://clinicaltrials.gov/study/NCT06745128", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.846Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.132Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06260722", "record": "Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)", "subtitle": "NCT06260722", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: Retatrutide; Semaglutide", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1250", "nctId": "NCT06260722" }, "jurisdiction": null, "date": "2026-09-28T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06260722", "url": "https://clinicaltrials.gov/study/NCT06260722", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.308Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07794579", "record": "ATTAIN-NOW: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity", "subtitle": "NCT07794579", "detail": "Conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "2001", "nctId": "NCT07794579" }, "jurisdiction": null, "date": "2026-09-28T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07794579", "url": "https://clinicaltrials.gov/study/NCT07794579", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.319Z", "change": null, "origin": "automated" }, { "key": "trial:NCT03407079", "record": "Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)", "subtitle": "NCT03407079", "detail": "Conditions: Healthy Volunteers; Overweight. Interventions: Sucralose; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", "enrollment": "150", "nctId": "NCT03407079" }, "jurisdiction": null, "date": "2026-09-28T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT03407079", "url": "https://clinicaltrials.gov/study/NCT03407079", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:17.129Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:17.604Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07078838", "record": "Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer", "subtitle": "NCT07078838", "detail": "Conditions: Endometrial Cancer; Endometrial Intraepithelial Neoplasia; Grade 1 Endometrial Endometrioid Carcinoma. Interventions: Tirzepatide", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "UNC Lineberger Comprehensive Cancer Center", "enrollment": "40", "nctId": "NCT07078838" }, "jurisdiction": null, "date": "2026-09-28T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07078838", "url": "https://clinicaltrials.gov/study/NCT07078838", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.846Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.108Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06700538", "record": "A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus", "subtitle": "NCT06700538", "detail": "Conditions: Obesity. Interventions: ARO-INHBE; Placebo; Tirzepatide", "status": "Recruiting", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "Arrowhead Pharmaceuticals", "enrollment": "180", "nctId": "NCT06700538" }, "jurisdiction": null, "date": "2026-09-25T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06700538", "url": "https://clinicaltrials.gov/study/NCT06700538", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.846Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.192Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07817875", "record": "Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)", "subtitle": "NCT07817875", "detail": "Conditions: Obesity. Interventions: Tirzepatide; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "150", "nctId": "NCT07817875" }, "jurisdiction": null, "date": "2026-09-25T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07817875", "url": "https://clinicaltrials.gov/study/NCT07817875", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.846Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.170Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07035093", "record": "TRIUMPH-7: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain", "subtitle": "NCT07035093", "detail": "Conditions: Obesity; Overweight; Chronic Low Back Pain (CLBP). Interventions: Retatrutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "586", "nctId": "NCT07035093" }, "jurisdiction": null, "date": "2026-09-25T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07035093", "url": "https://clinicaltrials.gov/study/NCT07035093", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.328Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07668336", "record": "ACHIEVE-PEDS: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes", "subtitle": "NCT07668336", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: Orforglipron; Dulaglutide", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "170", "nctId": "NCT07668336" }, "jurisdiction": null, "date": "2026-09-25T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07668336", "url": "https://clinicaltrials.gov/study/NCT07668336", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.338Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06937099", "record": "COMMIT-CD: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight", "subtitle": "NCT06937099", "detail": "Conditions: Crohn's Disease; Obesity or Overweight. Interventions: Mirikizumab; Mirikizumab; Tirzepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "290", "nctId": "NCT06937099" }, "jurisdiction": null, "date": "2026-09-24T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06937099", "url": "https://clinicaltrials.gov/study/NCT06937099", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.846Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.312Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07265752", "record": "Tirzepatide for the Treatment of Cannabis Use Disorder", "subtitle": "NCT07265752", "detail": "Conditions: Cannabis Use Disorder. Interventions: Tirzepatide; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "Brigham and Women's Hospital", "enrollment": "6", "nctId": "NCT07265752" }, "jurisdiction": null, "date": "2026-09-24T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07265752", "url": "https://clinicaltrials.gov/study/NCT07265752", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.846Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.290Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06937086", "record": "COMMIT-UC: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study", "subtitle": "NCT06937086", "detail": "Conditions: Ulcerative Colitis; Obesity or Overweight. Interventions: Mirikizumab; Mirikizumab; Tirzepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "350", "nctId": "NCT06937086" }, "jurisdiction": null, "date": "2026-09-24T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06937086", "url": "https://clinicaltrials.gov/study/NCT06937086", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.846Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.270Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06439277", "record": "A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)", "subtitle": "NCT06439277", "detail": "Conditions: Obesity; Weight Gain. Interventions: Tirzepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "300", "nctId": "NCT06439277" }, "jurisdiction": null, "date": "2026-09-24T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06439277", "url": "https://clinicaltrials.gov/study/NCT06439277", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.846Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.252Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06383390", "record": "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)", "subtitle": "NCT06383390", "detail": "Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD). Interventions: Retatrutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "10000", "nctId": "NCT06383390" }, "jurisdiction": null, "date": "2026-09-24T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06383390", "url": "https://clinicaltrials.gov/study/NCT06383390", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.348Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06672549", "record": "ADVANCE: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)", "subtitle": "NCT06672549", "detail": "Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "125", "nctId": "NCT06672549" }, "jurisdiction": null, "date": "2026-09-24T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06672549", "url": "https://clinicaltrials.gov/study/NCT06672549", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.356Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06131372", "record": "A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo", "subtitle": "NCT06131372", "detail": "Conditions: Chronic Kidney Disease; Type 2 Diabetes; Obesity. Interventions: Cagrilintide; Semaglutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Novo Nordisk A/S", "enrollment": "626", "nctId": "NCT06131372" }, "jurisdiction": null, "date": "2026-09-24T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06131372", "url": "https://clinicaltrials.gov/study/NCT06131372", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:17.756Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:17.964Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07165028", "record": "A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)", "subtitle": "NCT07165028", "detail": "Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease. Interventions: Tirzepatide; Retatrutide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "4500", "nctId": "NCT07165028" }, "jurisdiction": null, "date": "2026-09-22T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07165028", "url": "https://clinicaltrials.gov/study/NCT07165028", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.367Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07202884", "record": "RESTRAIN-SUI: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight", "subtitle": "NCT07202884", "detail": "Conditions: Urinary Incontinence,Stress. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1000", "nctId": "NCT07202884" }, "jurisdiction": null, "date": "2026-09-22T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07202884", "url": "https://clinicaltrials.gov/study/NCT07202884", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.453Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07223593", "record": "ATTAIN-PAD: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease", "subtitle": "NCT07223593", "detail": "Conditions: Peripheral Arterial Disease. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1205", "nctId": "NCT07223593" }, "jurisdiction": null, "date": "2026-09-22T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07223593", "url": "https://clinicaltrials.gov/study/NCT07223593", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.433Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07613307", "record": "ACHIEVE-RAM: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting", "subtitle": "NCT07613307", "detail": "Conditions: Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Metabolic Diseases; Endocr…. Interventions: Orforglipron", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "130", "nctId": "NCT07613307" }, "jurisdiction": null, "date": "2026-09-22T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07613307", "url": "https://clinicaltrials.gov/study/NCT07613307", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.414Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07153471", "record": "ATTAIN-OA PAIN: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee", "subtitle": "NCT07153471", "detail": "Conditions: Osteoarthritis. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "800", "nctId": "NCT07153471" }, "jurisdiction": null, "date": "2026-09-22T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07153471", "url": "https://clinicaltrials.gov/study/NCT07153471", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.393Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07241390", "record": "A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)", "subtitle": "NCT07241390", "detail": "Conditions: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "7140", "nctId": "NCT07241390" }, "jurisdiction": null, "date": "2026-09-22T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07241390", "url": "https://clinicaltrials.gov/study/NCT07241390", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.375Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07392190", "record": "ENLIGHTEN-6: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin", "subtitle": "NCT07392190", "detail": "Conditions: Overweight; Obesity. Interventions: Eloralintide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "900", "nctId": "NCT07392190" }, "jurisdiction": null, "date": "2026-09-22T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07392190", "url": "https://clinicaltrials.gov/study/NCT07392190", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:17.756Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:17.981Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07225829", "record": "INFLAM MOTION: A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis", "subtitle": "NCT07225829", "detail": "Conditions: Knee Osteoarthritis; Synovitis of Knee. Interventions: 4P004; Placebo (NaCl 0.9%)", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "4Moving Biotech", "enrollment": "129", "nctId": "NCT07225829" }, "jurisdiction": null, "date": "2026-09-21T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07225829", "url": "https://clinicaltrials.gov/study/NCT07225829", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.824Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.846Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06045221", "record": "ACHIEVE-3: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin", "subtitle": "NCT06045221", "detail": "Conditions: Type 2 Diabetes. Interventions: Orforglipron; Semaglutide", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1698", "nctId": "NCT06045221" }, "jurisdiction": null, "date": "2026-09-15T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06045221", "url": "https://clinicaltrials.gov/study/NCT06045221", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.474Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06649045", "record": "ATTAIN-OSA: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight", "subtitle": "NCT06649045", "detail": "Conditions: OSA; Overweight or Obesity. Interventions: Orforglipron; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "712", "nctId": "NCT06649045" }, "jurisdiction": null, "date": "2026-09-14T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06649045", "url": "https://clinicaltrials.gov/study/NCT06649045", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.500Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07815678", "record": "First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671", "subtitle": "NCT07815678", "detail": "Conditions: Obesity. Interventions: ACCG-2671; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics", "enrollment": "164", "nctId": "NCT07815678" }, "jurisdiction": null, "date": "2026-09-14T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07815678", "url": "https://clinicaltrials.gov/study/NCT07815678", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:17.756Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.076Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07575932", "record": "SOLIS-1: A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity", "subtitle": "NCT07575932", "detail": "Conditions: Overweight; Obesity; Overweight and/or Obesity; Overweight or Obesity; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseas…. Interventions: PF-08653945; PF-08653944; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Pfizer", "enrollment": "940", "nctId": "NCT07575932" }, "jurisdiction": null, "date": "2026-09-14T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07575932", "url": "https://clinicaltrials.gov/study/NCT07575932", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:17.756Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.060Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06797869", "record": "A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy", "subtitle": "NCT06797869", "detail": "Conditions: Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy. Interventions: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Novo Nordisk A/S", "enrollment": "142", "nctId": "NCT06797869" }, "jurisdiction": null, "date": "2026-09-10T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06797869", "url": "https://clinicaltrials.gov/study/NCT06797869", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:17.756Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.113Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07282613", "record": "REIMAGINEYOUNG: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes", "subtitle": "NCT07282613", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "80", "nctId": "NCT07282613" }, "jurisdiction": null, "date": "2026-09-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07282613", "url": "https://clinicaltrials.gov/study/NCT07282613", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:17.756Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.168Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06926842", "record": "Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)", "subtitle": "NCT06926842", "detail": "Conditions: Overweight; Type 2 Diabetes; Obesity. Interventions: Petrelintide; Placebo", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Zealand Pharma", "enrollment": "221", "nctId": "NCT06926842" }, "jurisdiction": null, "date": "2026-09-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06926842", "url": "https://clinicaltrials.gov/study/NCT06926842", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:17.756Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.149Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05872620", "record": "ATTAIN-2: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes", "subtitle": "NCT05872620", "detail": "Conditions: Obesity; Overweight; Type 2 Diabetes. Interventions: Orforglipron; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1613", "nctId": "NCT05872620" }, "jurisdiction": null, "date": "2026-09-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05872620", "url": "https://clinicaltrials.gov/study/NCT05872620", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.540Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05971940", "record": "ACHIEVE-1: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone", "subtitle": "NCT05971940", "detail": "Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "559", "nctId": "NCT05971940" }, "jurisdiction": null, "date": "2026-09-03T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05971940", "url": "https://clinicaltrials.gov/study/NCT05971940", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.560Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07790861", "record": "ATTAIN-CN: A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems", "subtitle": "NCT07790861", "detail": "Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "192", "nctId": "NCT07790861" }, "jurisdiction": null, "date": "2026-08-27T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07790861", "url": "https://clinicaltrials.gov/study/NCT07790861", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.603Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05965908", "record": "Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome", "subtitle": "NCT05965908", "detail": "Conditions: Polycystic Ovary. Interventions: liraglutide; Metformin", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Beni-Suef University", "enrollment": "183", "nctId": "NCT05965908" }, "jurisdiction": null, "date": "2026-08-25T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05965908", "url": "https://clinicaltrials.gov/study/NCT05965908", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.824Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.921Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06672939", "record": "A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities", "subtitle": "NCT06672939", "detail": "Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "150", "nctId": "NCT06672939" }, "jurisdiction": null, "date": "2026-08-24T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06672939", "url": "https://clinicaltrials.gov/study/NCT06672939", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.621Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05929066", "record": "TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight", "subtitle": "NCT05929066", "detail": "Conditions: Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea. Interventions: Retatrutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "2335", "nctId": "NCT05929066" }, "jurisdiction": null, "date": "2026-08-21T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05929066", "url": "https://clinicaltrials.gov/study/NCT05929066", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.385Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05869903", "record": "ATTAIN-1: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities", "subtitle": "NCT05869903", "detail": "Conditions: Obesity; Overweight; Overweight or Obesity. Interventions: Orforglipron; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "3127", "nctId": "NCT05869903" }, "jurisdiction": null, "date": "2026-08-14T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05869903", "url": "https://clinicaltrials.gov/study/NCT05869903", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.642Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06993792", "record": "A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes", "subtitle": "NCT06993792", "detail": "Conditions: Obesity; Overweight; Type 2 Diabetes. Interventions: Orforglipron; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1400", "nctId": "NCT06993792" }, "jurisdiction": null, "date": "2026-07-31T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06993792", "url": "https://clinicaltrials.gov/study/NCT06993792", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.660Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05929079", "record": "TRIUMPH-2: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight", "subtitle": "NCT05929079", "detail": "Conditions: Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea. Interventions: Retatrutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1152", "nctId": "NCT05929079" }, "jurisdiction": null, "date": "2026-07-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05929079", "url": "https://clinicaltrials.gov/study/NCT05929079", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.439Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05882045", "record": "TRIUMPH-3: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease", "subtitle": "NCT05882045", "detail": "Conditions: Obesity; Cardiovascular Diseases. Interventions: Retatrutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1946", "nctId": "NCT05882045" }, "jurisdiction": null, "date": "2026-07-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05882045", "url": "https://clinicaltrials.gov/study/NCT05882045", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.422Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06972459", "record": "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity", "subtitle": "NCT06972459", "detail": "Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "800", "nctId": "NCT06972459" }, "jurisdiction": null, "date": "2026-07-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06972459", "url": "https://clinicaltrials.gov/study/NCT06972459", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:18.678Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06297603", "record": "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)", "subtitle": "NCT06297603", "detail": "Conditions: Type 2 Diabetes. Interventions: Retatrutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "320", "nctId": "NCT06297603" }, "jurisdiction": null, "date": "2026-07-20T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06297603", "url": "https://clinicaltrials.gov/study/NCT06297603", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.504Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06662383", "record": "TRIUMPH-5: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity", "subtitle": "NCT06662383", "detail": "Conditions: Obesity. Interventions: Retatrutide; Tirzepatide", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "800", "nctId": "NCT06662383" }, "jurisdiction": null, "date": "2026-07-20T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06662383", "url": "https://clinicaltrials.gov/study/NCT06662383", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.459Z", "change": null, "origin": "automated" }, { "key": "trial:NCT04775082", "record": "SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity", "subtitle": "NCT04775082", "detail": "Conditions: Obesity. Interventions: Liraglutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "78", "nctId": "NCT04775082" }, "jurisdiction": null, "date": "2026-07-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT04775082", "url": "https://clinicaltrials.gov/study/NCT04775082", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.824Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.085Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07357415", "record": "TRIUMPH-9: A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight", "subtitle": "NCT07357415", "detail": "Conditions: Obesity; Overweight. Interventions: Retatrutide", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "600", "nctId": "NCT07357415" }, "jurisdiction": null, "date": "2026-06-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07357415", "url": "https://clinicaltrials.gov/study/NCT07357415", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.606Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07107334", "record": "A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia", "subtitle": "NCT07107334", "detail": "Conditions: Endometrioid Endometrial Adenocarcinoma. Interventions: Glucagon-like peptide 1 receptor agonist", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "University of Florida", "enrollment": "20", "nctId": "NCT07107334" }, "jurisdiction": null, "date": "2026-06-08T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07107334", "url": "https://clinicaltrials.gov/study/NCT07107334", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.824Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.141Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07613437", "record": "GLICH: GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial", "subtitle": "NCT07613437", "detail": "Conditions: Intracerebral Hemorrhage. Interventions: Semaglutide, 0.5 mg/mL", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "Chinese University of Hong Kong", "enrollment": "200", "nctId": "NCT07613437" }, "jurisdiction": null, "date": "2026-05-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07613437", "url": "https://clinicaltrials.gov/study/NCT07613437", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:18.824Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.159Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07232719", "record": "TRIUMPH-8: A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight", "subtitle": "NCT07232719", "detail": "Conditions: Obesity; Overweight. Interventions: Retatrutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "250", "nctId": "NCT07232719" }, "jurisdiction": null, "date": "2026-04-17T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07232719", "url": "https://clinicaltrials.gov/study/NCT07232719", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.626Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07467447", "record": "GZBF: Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight", "subtitle": "NCT07467447", "detail": "Conditions: Obesity. Interventions: Retatrutide (LY3437943); Placebo; Standardized diet and physical activity counseling throughout the study.", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Hudson Biotech", "enrollment": "300", "nctId": "NCT07467447" }, "jurisdiction": null, "date": "2026-03-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07467447", "url": "https://clinicaltrials.gov/study/NCT07467447", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.645Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06354660", "record": "Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)", "subtitle": "NCT06354660", "detail": "Conditions: Diabetes Type 2. Interventions: Retatrutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "537", "nctId": "NCT06354660" }, "jurisdiction": null, "date": "2026-03-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06354660", "url": "https://clinicaltrials.gov/study/NCT06354660", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.664Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06859268", "record": "TRIUMPH-6: A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity", "subtitle": "NCT06859268", "detail": "Conditions: Obesity. Interventions: Retatrutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "643", "nctId": "NCT06859268" }, "jurisdiction": null, "date": "2026-03-03T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06859268", "url": "https://clinicaltrials.gov/study/NCT06859268", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.684Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05931367", "record": "TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee", "subtitle": "NCT05931367", "detail": "Conditions: Obesity; Overweight; Osteo Arthritis Knee. Interventions: Retatrutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "445", "nctId": "NCT05931367" }, "jurisdiction": null, "date": "2026-01-21T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05931367", "url": "https://clinicaltrials.gov/study/NCT05931367", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.705Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05936151", "record": "A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "subtitle": "NCT05936151", "detail": "Conditions: Overweight or Obesity; CKD; Type 2 Diabetes. Interventions: Retatrutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Eli Lilly and Company", "enrollment": "146", "nctId": "NCT05936151" }, "jurisdiction": null, "date": "2025-11-25T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05936151", "url": "https://clinicaltrials.gov/study/NCT05936151", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:19.292Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:19.742Z", "change": null, "origin": "automated" } ] }